

W Ray Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3846970/publications.pdf>

Version: 2024-02-01

237
papers

26,797
citations

7096

78
h-index

6131

159
g-index

248
all docs

248
docs citations

248
times ranked

21328
citing authors

#	ARTICLE	IF	CITATIONS
1	The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care. <i>Hepatology</i> , 2023, 77, 256-267.	7.3	18
2	Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. <i>Hepatology</i> , 2022, 75, 1026-1037.	7.3	22
3	Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. <i>Journal of Hepatology</i> , 2022, 76, 186-194.	3.7	14
4	Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 230-232.	4.4	8
5	Author response to "MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era". <i>Gastroenterology</i> , 2022, , .	1.3	0
6	Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 828-835.	3.7	9
7	Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study. <i>Journal of General Internal Medicine</i> , 2022, 37, 3318-3324.	2.6	4
8	First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alafenamide. <i>Hepatology Communications</i> , 2022, 6, 1881-1894.	4.3	7
9	Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir? A knock-out is yet to be delivered? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1344-1345.	3.7	0
10	"Beyond MELD" Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation. <i>Journal of Hepatology</i> , 2022, 76, 1318-1329.	3.7	24
11	Introducing ELFIT (Exercise and Liver FITness): A Smartphone App to Prehabilitate and Monitor Liver Transplant Candidates. <i>Liver Transplantation</i> , 2021, 27, 502-512.	2.4	33
12	Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	1.0	4
13	Predicting Survival After Liver Transplantation: A Noble Pursuit or a Fool's Errand?. <i>Liver Transplantation</i> , 2021, 27, 789-790.	2.4	1
14	An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. <i>Hepatology</i> , 2021, 74, 607-626.	7.3	64
15	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1014-1048.	7.3	311
16	Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome. <i>Liver Transplantation</i> , 2021, 27, 1095-1105.	2.4	18
17	Correcting the sex disparity in access to liver transplantation: Lest perfect be the enemy of better. <i>American Journal of Transplantation</i> , 2021, 21, 3217-3218.	4.7	0
18	MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. <i>Gastroenterology</i> , 2021, 161, 1887-1895.e4.	1.3	180

#	ARTICLE	IF	CITATIONS
19	Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. <i>Hepatology Communications</i> , 2021, 5, 516-525.	4.3	7
20	Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 747-749.	4.4	20
21	Home-Based Physical Activity and Diet Intervention to Improve Physical Function in Advanced Liver Disease: A Randomized Pilot Trial. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3350-3359.	2.3	50
22	Reply to: "The decreasing predictive power of MELD in an era of changing etiology of liver disease". <i>American Journal of Transplantation</i> , 2020, 20, 901-902.	4.7	5
23	Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver—kidney Transplant as a Case Example. <i>Transplantation</i> , 2020, 104, 387-394.	1.0	13
24	Center Variation in Intention—to—Treat Survival Among Patients Listed for Liver Transplant. <i>Liver Transplantation</i> , 2020, 26, 1582-1593.	2.4	10
25	Prevalence of Chronic Hepatitis B Virus Infection in the United States. <i>American Journal of Gastroenterology</i> , 2020, 115, 1429-1438.	0.4	92
26	<p>Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 515-526.	1.9	9
27	Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time. <i>Clinical Liver Disease</i> , 2020, 15, 85-90.	2.1	18
28	Cadence From Physical Activity Trackers for Monitoring of Home—Based Exercise Intensity in Advanced Liver Disease. <i>Liver Transplantation</i> , 2020, 26, 718-721.	2.4	8
29	Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. <i>Hepatology</i> , 2020, 72, 2197-2205.	7.3	18
30	Tool to Aid Patients in Selecting a Liver Transplant Center. <i>Liver Transplantation</i> , 2020, 26, 337-348.	2.4	8
31	Exercise—Induced Hyperammonemia Does Not Precipitate Overt Hepatic Encephalopathy. <i>Hepatology</i> , 2020, 72, 778-780.	7.3	3
32	Introduction: Liver Disease in Asia. <i>Clinical Liver Disease</i> , 2020, 16, 223-226.	2.1	0
33	Migration of Patients for Liver Transplantation and Waitlist Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2347-2355.e5.	4.4	10
34	The interaction of nonalcoholic fatty liver disease and smoking on mortality among adults in the United States. <i>Liver International</i> , 2019, 39, 1202-1206.	3.9	5
35	Impact of Sofosbuvir—Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection. <i>Pharmacotherapy</i> , 2019, 39, 424-432.	2.6	4
36	Diagnosis and Management of Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 48-63.	0.4	100

#	ARTICLE	IF	CITATIONS
37	A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study. <i>Digestive Diseases and Sciences</i> , 2019, 64, 358-366.	2.3	7
38	De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era. <i>Hepatology</i> , 2018, 68, 1288-1297.	7.3	9
39	Liver Simulated Allocation Modeling. <i>Transplantation</i> , 2018, 102, 769-774.	1.0	15
40	Improved posttransplant mortality after share 35 for liver transplantation. <i>Hepatology</i> , 2018, 67, 273-281.	7.3	40
41	Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. <i>Clinics in Liver Disease</i> , 2018, 22, 133-140.	2.1	153
42	Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list. <i>Liver Transplantation</i> , 2018, 24, 122-139.	2.4	147
43	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <i>Hepatology</i> , 2018, 68, 78-88.	7.3	45
44	Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States. <i>Transplantation</i> , 2018, 102, 454-460.	1.0	34
45	Short Sleep Duration Is Associated With Abnormal Serum Aminotransferase Activities and Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 588-590.	4.4	18
46	Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. <i>Liver Transplantation</i> , 2018, 24, 735-743.	2.4	21
47	Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1282-1289.	3.7	21
48	Hemoglobin A1c Has Suboptimal Performance to Diagnose and Monitor Diabetes Mellitus in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3498-3508.	2.3	12
49	Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era. <i>Clinics in Liver Disease</i> , 2018, 22, 563-578.	2.1	32
50	Comparing Simultaneous Liver-Kidney Transplant Strategies. <i>Transplantation</i> , 2018, 102, e219-e228.	1.0	9
51	Epidemiology of Hepatitis B Virus Infection in the United States. <i>Clinical Liver Disease</i> , 2018, 12, 1-4.	2.1	44
52	Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. <i>Transplantation</i> , 2018, 102, 1710-1716.	1.0	103
53	Hepatitis B Virus Reactivation and Management of Patients Undergoing Immunosuppression. , 2018, , 315-341.		0
54	Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. <i>Liver Transplantation</i> , 2017, 23, 733-740.	2.4	39

#	ARTICLE	IF	CITATIONS
55	Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. <i>Journal of Hepatology</i> , 2017, 67, 517-525.	3.7	31
56	Utility in Treating Kidney Failure in End-Stage Liver Disease With Simultaneous Liver-Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1111-1119.	1.0	26
57	Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. <i>American Journal of Epidemiology</i> , 2017, 186, 356-366.	3.4	15
58	Reduction in liver transplant waitlisting in the era of direct-acting antiviral therapy. <i>Hepatology</i> , 2017, 65, 804-812.	7.3	197
59	Nonobese Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 474-485.	4.4	262
60	Impact of direct-acting antiviral agents-induced SVR on the long-term burden of hepatocellular carcinoma in chronic hepatitis C cirrhosis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 230-230.	1.6	0
61	Epidemiology and Healthcare Burden of Acute-on-Chronic Liver Failure. <i>Seminars in Liver Disease</i> , 2016, 36, 123-126.	3.6	22
62	Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. <i>Hepatology</i> , 2016, 64, 2165-2172.	7.3	138
63	Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the <sc>US</sc> â€” the <sc>ENUMERATE</sc> study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 134-144.	3.7	63
64	Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. <i>American Journal of Gastroenterology</i> , 2016, 111, 1573-1580.	0.4	61
65	Management of renal failure in end-stage liver disease: A critical appraisal. <i>Liver Transplantation</i> , 2016, 22, 1710-1719.	2.4	10
66	Predicting Outcomes on the Liver Transplant Waiting List in the United States. <i>Transplantation</i> , 2016, 100, 2153-2159.	1.0	25
67	Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 1297-1304.	0.4	39
68	Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2016, 64, 1027-1032.	3.7	54
69	Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 684-695.e5.	1.3	178
70	The Epidemiology of Liver Diseases Unique to Pregnancy in the US Community: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 287-294.e2.	4.4	64
71	Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2016, 64, 773-780.	3.7	223
72	Potential Efficacy of Pegylated Interferon-Î± and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B. <i>Gut and Liver</i> , 2016, 10, 611-616.	2.9	4

#	ARTICLE	IF	CITATIONS
73	Diabetes and prediabetes in patients with hepatitis B residing in North America. <i>Hepatology</i> , 2015, 62, 1364-1374.	7.3	29
74	Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients. <i>Transplantation</i> , 2015, 99, 1431-1435.	1.0	37
75	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Cancer</i> , 2015, 121, 3631-3638.	4.1	173
76	Low Level of Hepatitis B Virus Screening Among Patients Receiving Chemotherapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 970-975.	4.4	25
77	A glass half full: Implications of screening for hepatitis C virus in the era of highly effective antiviral therapy. <i>Hepatology</i> , 2015, 61, 1455-1458.	7.3	6
78	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	12.1	405
79	Reply to prediction of hepatocellular carcinoma: Using a complex risk model or assisting for smoking cessation?. <i>Cancer</i> , 2015, 121, 1150-1150.	4.1	1
80	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.	3.7	571
81	Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. <i>Hepatology</i> , 2015, 61, 1643-1650.	7.3	107
82	Reply to: "Chronic kidney disease (CKD) and NAFLD: Time for awareness and screening". <i>Journal of Hepatology</i> , 2015, 62, 984-985.	3.7	2
83	Corrigendum to "Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites" [<i>Hepatology</i> 2015;62:968-974]. <i>Journal of Hepatology</i> , 2015, 63, 290.	3.7	9
84	Reply to: "Chronic kidney disease after liver transplantation". <i>Journal of Hepatology</i> , 2015, 62, 244-245.	3.7	0
85	Current and Future Burden of Chronic Nonmalignant Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2031-2041.	4.4	111
86	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 183-192.	4.4	90
87	Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 248-257.	2.4	25
88	Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH). <i>PLoS ONE</i> , 2015, 10, e0138374.	2.5	1
89	Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model. <i>Cancer</i> , 2014, 120, 3485-3493.	4.1	125
90	Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 687-697.	2.4	43

#	ARTICLE	IF	CITATIONS
91	Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study. <i>Liver International</i> , 2014, 34, e317-23.	3.9	19
92	Survival of Recipients of Livers From Donation After Circulatory Death Who Are Relisted and Undergo Retransplant for Graft Failure. <i>American Journal of Transplantation</i> , 2014, 14, 1120-1128.	4.7	16
93	Coffee: A Panacea or Snake Oil for the Liver?. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1569-1571.	4.4	3
94	The impact of hepatitis C burden: an evidence-based approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 518-531.	3.7	107
95	Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. <i>Mayo Clinic Proceedings</i> , 2014, 89, 595-601.	3.0	3
96	Chronic kidney disease and associated mortality after liver transplantation – A time-dependent analysis using measured glomerular filtration rate. <i>Journal of Hepatology</i> , 2014, 61, 286-292.	3.7	141
97	Management of Hepatic Encephalopathy in the Hospital. <i>Mayo Clinic Proceedings</i> , 2014, 89, 241-253.	3.0	91
98	Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. <i>Hepatology</i> , 2014, 60, 2008-2016.	7.3	145
99	Toward an Improved Definition of Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2014, 147, 4-10.	1.3	255
100	In the eye of the B-holder: Natural history of chronic hepatitis B. <i>Hepatology</i> , 2013, 58, 6-8.	7.3	9
101	Impact of the center on graft failure after liver transplantation. <i>Liver Transplantation</i> , 2013, 19, 957-964.	2.4	41
102	An ALTer Ego of Serum ALT: Is It More Than a Marker of Liver Inflammation?. <i>Gastroenterology</i> , 2013, 145, 1191-1193.	1.3	3
103	Efficacy and Safety of Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1655-1660.e1.	4.4	15
104	Predicting Clinical Outcomes With Elastography in Primary Biliary Cirrhosis: One Step Closer?. <i>Gastroenterology</i> , 2013, 144, 851-852.	1.3	1
105	Underestimation of Liver-Related Mortality in the United States. <i>Gastroenterology</i> , 2013, 145, 375-382.e2.	1.3	253
106	Risk factors for intrahepatic cholangiocarcinoma: Association between metformin use and reduced cancer risk. <i>Hepatology</i> , 2013, 57, 648-655.	7.3	120
107	Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: Noninvasive Assessment with MR Elastography. <i>Radiology</i> , 2013, 268, 411-419.	7.3	203
108	Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. <i>Liver Transplantation</i> , 2013, 19, 521-528.	2.4	25

#	ARTICLE	IF	CITATIONS
109	Recurrent Hepatocellular Carcinoma: It's the Virus!. <i>Journal of Clinical Oncology</i> , 2013, 31, 3621-3622.	1.6	13
110	Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. <i>Hepatology</i> , 2013, 57, 1357-1365.	7.3	614
111	Hepatitis B Screening and Vaccination Practices in Asian American Primary Care. <i>Gut and Liver</i> , 2013, 7, 450-457.	2.9	22
112	Hepatitis B Screening in a US Academic Primary Care Practice. <i>Archives of Internal Medicine</i> , 2012, 172, 1517.	3.8	3
113	Biliary Tract Cancers in Olmsted County, Minnesota, 1976-2008. <i>American Journal of Gastroenterology</i> , 2012, 107, 1256-1262.	0.4	68
114	Surveillance for Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 16-21.	4.4	31
115	Hepatocellular Carcinoma in Olmsted County, Minnesota, 1976-2008. <i>Mayo Clinic Proceedings</i> , 2012, 87, 9-16.	3.0	39
116	Hospitalization for Underage Drinkers in the United States. <i>Journal of Adolescent Health</i> , 2012, 50, 648-650.	2.5	14
117	Evaluation of Elevated Liver Enzymes. <i>Clinics in Liver Disease</i> , 2012, 16, 183-198.	2.1	52
118	Kidney, Pancreas and Liver Allocation and Distribution in the United States. <i>American Journal of Transplantation</i> , 2012, 12, 3191-3212.	4.7	92
119	Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers. <i>Gastroenterology</i> , 2012, 143, 88-98.e3.	1.3	475
120	Development of organ-specific donor risk indices. <i>Liver Transplantation</i> , 2012, 18, 395-404.	2.4	66
121	Nonalcoholic fatty liver disease is associated with coronary artery calcification. <i>Hepatology</i> , 2012, 56, 605-613.	7.3	259
122	Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. <i>Hepatology</i> , 2012, 56, 972-981.	7.3	119
123	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 614-621.	7.3	83
124	Simultaneous Liver-Kidney Transplantation Summit: Current State and Future Directions. <i>American Journal of Transplantation</i> , 2012, 12, 2901-2908.	4.7	225
125	Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: A systematic review and meta-analysis. <i>Liver Transplantation</i> , 2012, 18, 323-331.	2.4	66
126	Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 617-623.e1.	4.4	116

#	ARTICLE	IF	CITATIONS
127	Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 64-70.	4.4	216
128	Impact of Obesity on Alcoholic Hepatitis: A Population Based Study. <i>Gastroenterology</i> , 2011, 140, S-914.	1.3	2
129	A Revised Model for End-Stage Liver Disease Optimizes Prediction of Mortality Among Patients Awaiting Liver Transplantation. <i>Gastroenterology</i> , 2011, 140, 1952-1960.	1.3	131
130	Born to be Wild or Just Confused? Genetic Predisposition to Hepatic Encephalopathy. <i>Gastroenterology</i> , 2011, 140, 2137-2138.	1.3	0
131	Model for End-Stage Liver Disease: End of the First Decade. <i>Clinics in Liver Disease</i> , 2011, 15, 685-698.	2.1	52
132	Many Patients With Primary Sclerosing Cholangitis and Increased Serum Levels of Carbohydrate Antigen 19-9 Do Not Have Cholangiocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 434-439.e1.	4.4	108
133	Drug therapy: Telaprevir. <i>Hepatology</i> , 2011, 54, 1463-1469.	7.3	6
134	Treatment of Hepatitis B Virus-Associated Nephropathy. <i>Nephron Clinical Practice</i> , 2011, 119, c41-c49.	2.3	41
135	The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. <i>Journal of Medical Economics</i> , 2011, 14, 253-261.	2.1	60
136	Issues in Transplantation of Patients with Chronic Liver Failure. , 2011, , 521-539.		0
137	Organ allocation for chronic liver disease: model for end-stage liver disease and beyond. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 209-213.	2.3	35
138	Impact of Depressive Symptoms and Their Treatment on Completing Antiviral Treatment in Patients With Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e178-e185.	2.2	18
139	Efficacy, effectiveness, and comparative effectiveness in liver disease. <i>Hepatology</i> , 2010, 52, 403-407.	7.3	37
140	Use of sirolimus in liver transplant recipients with renal insufficiency: A systematic review and meta-analysis. <i>Hepatology</i> , 2010, 52, 1360-1370.	7.3	78
141	Race and receipt of liver transplantation: Location matters. <i>Liver Transplantation</i> , 2010, 16, 1009-1012.	2.4	9
142	Alcoholic Liver Disease-Related Mortality in the United States: 1980-2003. <i>American Journal of Gastroenterology</i> , 2010, 105, 1782-1787.	0.4	70
143	Endothelial Nitric Oxide Synthase Gene Variation Associated With Chronic Kidney Disease After Liver Transplant. <i>Mayo Clinic Proceedings</i> , 2010, 85, 814-820.	3.0	4
144	Donor Race Does Not Predict Graft Failure After Liver Transplantation. <i>Gastroenterology</i> , 2010, 138, 2341-2347.	1.3	21

#	ARTICLE	IF	CITATIONS
145	Predicting Response to Pegylated Interferon/Ribavirin-Based Therapy in Genotype 1 Chronic Hepatitis C Patients: Results of 3 Independent Genome-Wide Association Studies. <i>Gastroenterology</i> , 2010, 138, 1622-1624.	1.3	6
146	Rifaximin in Hepatic Encephalopathy: Is an Ounce of Prevention Worth a Pretty Penny?. <i>Gastroenterology</i> , 2010, 139, 1416-1418.	1.3	4
147	Serum sodium, renal function, and survival of patients with end-stage liver disease. <i>Journal of Hepatology</i> , 2010, 52, 523-528.	3.7	62
148	Humanistic and economic impacts of hepatitis C infection in the United States. <i>Journal of Medical Economics</i> , 2010, 13, 709-718.	2.1	69
149	Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. <i>Gut and Liver</i> , 2010, 4, 537-542.	2.9	4
150	Reports from today's health care environment on the implementation of screening, diagnosis, and treatment recommendations. <i>Journal of Family Practice</i> , 2010, 59, S43-50.	0.2	1
151	Transforming the current infrastructure for combating HBV and HCV infections. <i>Journal of Family Practice</i> , 2010, 59, S65-70.	0.2	2
152	Impact of pretransplant hyponatremia on outcome following liver transplantation. <i>Hepatology</i> , 2009, 49, 1610-1615.	7.3	114
153	Epidemiology of hepatitis B in the United States. <i>Hepatology</i> , 2009, 49, S28-S34.	7.3	177
154	Survival benefit of liver transplantation: One size fits all or fits none?. <i>Hepatology</i> , 2009, 50, 352-354.	7.3	4
155	Hepatitis C nonresponders: Re-treat or retreat?. <i>Hepatology</i> , 2009, 50, 1307-1309.	7.3	2
156	The Clip Score: Is it time to be clipped away?. <i>Liver International</i> , 2009, 29, 2-3.	3.9	1
157	Increased Prevalence and Mortality in Undiagnosed Celiac Disease. <i>Gastroenterology</i> , 2009, 137, 88-93.	1.3	675
158	Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States. <i>Gastroenterology</i> , 2009, 137, 1680-1686.	1.3	149
159	Editorial: Hyponatremia in Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2009, 104, 1390-1391.	0.4	10
160	The International Normalized Ratio of Prothrombin Time in the Model for End-Stage Liver Disease Score: A Reliable Measure. <i>Clinics in Liver Disease</i> , 2009, 13, 63-66.	2.1	8
161	Mortality attributable to cholestatic liver disease in the United States. <i>Hepatology</i> , 2008, 47, 1241-1247.	7.3	37
162	Serum aminotransferase activity and mortality risk in a United States community. <i>Hepatology</i> , 2008, 47, 880-887.	7.3	157

#	ARTICLE	IF	CITATIONS
163	Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. <i>Hepatology</i> , 2008, 47, 1363-1370.	7.3	630
164	Reply:. <i>Hepatology</i> , 2008, 48, 688-688.	7.3	2
165	Benefits of "the benefit model" in liver transplantation. <i>Hepatology</i> , 2008, 48, 697-698.	7.3	21
166	The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease. <i>Clinics in Liver Disease</i> , 2008, 12, 733-746.	2.1	262
167	Hepatic Vein Pressure Gradient > 10 mm Hg: Prognostic or Reflective?. <i>Gastroenterology</i> , 2008, 134, 641.	1.3	2
168	Mortality in Patients With Hepatitis C. <i>Gastroenterology</i> , 2008, 134, 635-637.	1.3	0
169	Clinical Implications of Short-Term Variability in Liver Function Test Results. <i>Gastroenterology</i> , 2008, 135, 1010-1011.	1.3	3
170	Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List. <i>New England Journal of Medicine</i> , 2008, 359, 1018-1026.	27.0	1,184
171	Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. <i>Gut</i> , 2008, 57, 814-820.	12.1	211
172	Natural History of Hepatitis B Virus Infection: An Update for Clinicians. <i>Mayo Clinic Proceedings</i> , 2007, 82, 967-975.	3.0	188
173	Risk Factors for Mortality After Surgery in Patients With Cirrhosis. <i>Gastroenterology</i> , 2007, 132, 1261-1269.	1.3	484
174	The model for end-stage liver disease (MELD). <i>Hepatology</i> , 2007, 45, 797-805.	7.3	1,365
175	Survival after liver transplantation: Is racial disparity inevitable?. <i>Hepatology</i> , 2007, 46, 1491-1497.	7.3	21
176	Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. <i>Liver Transplantation</i> , 2007, 13, 1366-1371.	2.4	236
177	Can the model for end-stage liver disease be used to predict the prognosis in patients with Budd-Chiari syndrome?. <i>Liver Transplantation</i> , 2007, 13, 867-874.	2.4	29
178	Epidemiology of hepatitis B in the United States. <i>Current Hepatitis Reports</i> , 2007, 6, 3-8.	0.3	0
179	Evidence-Based Incorporation of Serum Sodium Concentration Into MELD. <i>Gastroenterology</i> , 2006, 130, 1652-1660.	1.3	632
180	Deaths on the liver transplant waiting list: An analysis of competing risks. <i>Hepatology</i> , 2006, 43, 345-351.	7.3	133

#	ARTICLE	IF	CITATIONS
181	Is coffee or tea good for your liver?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006, 3, 482-483.	1.7	2
182	Employment and Health Insurance in Long-Term Liver Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 1901-1908.	4.7	36
183	MELD accurately predicts mortality in patients with alcoholic hepatitis. <i>Hepatology</i> , 2005, 41, 353-358.	7.3	458
184	Reply:. <i>Hepatology</i> , 2005, 42, 495-496.	7.3	1
185	The Use of Decision Analytic Models to Inform Clinical Decision Making in the Management of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2005, 9, 225-234.	2.1	1
186	Mortality and Hospital Utilization for Hepatocellular Carcinoma in the United States. <i>Gastroenterology</i> , 2005, 129, 486-493.	1.3	1
187	Mortality and Hospital Utilization for Hepatocellular Carcinoma in the United States. <i>Gastroenterology</i> , 2005, 129, 486-493.	1.3	105
188	Health Status Assessment and Economic Analyses in Cirrhosis and Portal Hypertension. , 2005, , 469-484.		0
189	Liver Transplantation for Primary Biliary Cirrhosis. , 2005, , 177-186.		0
190	Management of Patients With Hepatitis C in a Community Population: Diagnosis, Discussions, and Decisions to Treat. <i>Annals of Family Medicine</i> , 2004, 2, 116-124.	1.9	48
191	Predicting Survival among Patients Listed for Liver Transplantation: An Assessment of Serial MELD Measurements. <i>American Journal of Transplantation</i> , 2004, 4, 1798-1804.	4.7	105
192	MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. <i>Hepatology</i> , 2004, 39, 764-769.	7.3	192
193	Changing epidemiology of hepatitis B in a U.S. community. <i>Hepatology</i> , 2004, 39, 811-816.	7.3	83
194	Outcome of liver transplantation for hepatitis B in the United States. <i>Liver Transplantation</i> , 2004, 10, 968-974.	2.4	180
195	The impact of competing risks on the observed rate of chronic hepatitis C progression. <i>Gastroenterology</i> , 2004, 127, 749-755.	1.3	26
196	Primary biliary cirrhosis: an infectious disease caused by <i>Chlamydia pneumoniae</i> ?. <i>Journal of Hepatology</i> , 2004, 40, 380-384.	3.7	112
197	A glossary of economic terms. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 563-565.	1.6	4
198	Cost-effectiveness analysis and incremental cost-effectiveness ratios. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 519-526.	1.6	42

#	ARTICLE	IF	CITATIONS
199	Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. <i>Hepatology</i> , 2003, 37, 897-901.	7.3	225
200	Pretransplantation disease severity and posttransplantation outcome. <i>Liver Transplantation</i> , 2003, 9, 124-125.	2.4	5
201	Is the change in MELD score a better indicator of mortality than baseline MELD score?. <i>Liver Transplantation</i> , 2003, 9, 19-21.	2.4	32
202	Liver transplantation is effective, but is it cost-effective?. <i>Liver Transplantation</i> , 2003, 9, 1308-1311.	2.4	6
203	Effect of Minimal Listing Criteria on Waiting List Registration for Liver Transplantation: A Process-Outcome Analysis. <i>Mayo Clinic Proceedings</i> , 2003, 78, 431-435.	3.0	5
204	Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a united states community. <i>Gastroenterology</i> , 2003, 125, 1364-1369.	1.3	402
205	Medical and economic impact of autoimmune hepatitis. <i>Clinics in Liver Disease</i> , 2002, 6, 649-667.	2.1	8
206	Motion "The Available Treatments for Hepatitis C Are Cost Effective: Arguments against the Motion. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2002, 16, 710-715.	1.7	4
207	Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. <i>Health Economics (United Kingdom)</i> , 2002, 11, 551-566.	1.7	12
208	The burden of hepatitis C in the United States. <i>Hepatology</i> , 2002, 36, S30-S34.	7.3	303
209	Global epidemiology and burden of hepatitis C. <i>Microbes and Infection</i> , 2002, 4, 1219-1225.	1.9	118
210	The burden of hepatitis C in the United States. <i>Hepatology</i> , 2002, 36, s30-s34.	7.3	291
211	Development and maintenance of a community-based hepatitis C registry. <i>American Journal of Managed Care</i> , 2002, 8, 253-61.	1.1	7
212	Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. <i>Journal of Family Practice</i> , 2002, 51, 135-40.	0.2	28
213	Models predicting the natural history of cirrhosis and need for liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2001, 6, 107-113.	1.6	3
214	Outcome of hospital care of liver disease associated with hepatitis C in the United States. <i>Hepatology</i> , 2001, 33, 201-206.	7.3	93
215	A model to predict survival in patients with end-stage liver disease. <i>Hepatology</i> , 2001, 33, 464-470.	7.3	4,112
216	Reply:. <i>Hepatology</i> , 2001, 34, 215-216.	7.3	3

#	ARTICLE	IF	CITATIONS
217	MELD and PELD: Application of survival models to liver allocation. Liver Transplantation, 2001, 7, 567-580.	2.4	753
218	A Revised Natural History Model for Primary Sclerosing Cholangitis. Mayo Clinic Proceedings, 2000, 75, 688-694.	3.0	285
219	Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C. Hepatology, 2000, 31, 807-808.	7.3	6
220	Reliability and Validity of the NIDDK-QA Instrument in the Assessment of Quality of Life in Ambulatory Patients With Cholestatic Liver Disease. Hepatology, 2000, 32, 924-929.	7.3	45
221	Predicting clinical and economic outcomes after liver transplantation using the mayo primary sclerosing cholangitis model and child-pugh score. Liver Transplantation, 2000, 6, 753-758.	2.4	33
222	Quality of life instruments for liver transplant recipients: Too many choices?. Liver Transplantation, 2000, 6, 784-785.	2.4	5
223	Adaptation of the Mayo Primary Biliary Cirrhosis Natural History Model for Application in Liver Transplant Candidates. Liver Transplantation, 2000, 6, 489-494.	2.4	50
224	Accuracy of Doppler Echocardiography in the Assessment of Pulmonary Hypertension in Liver Transplant Candidates. Liver Transplantation, 2000, 6, 453-458.	2.4	176
225	Timing of Liver Transplantation. Seminars in Liver Disease, 2000, 20, 451-464.	3.6	9
226	A Revised Natural History Model for Primary Sclerosing Cholangitis. Mayo Clinic Proceedings, 2000, 75, 688-694.	3.0	280
227	THE ECONOMIC IMPACT OF CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATION. Transplantation, 2000, 69, 357-361.	1.0	75
228	Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology, 1999, 29, 356-364.	7.3	185
229	The relative role of the child-pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology, 1999, 29, 1643-1648.	7.3	124
230	Hepatic retransplantation in cholestatic liver disease: Impact of the interval to retransplantation on survival and resource utilization. Hepatology, 1999, 30, 395-400.	7.3	69
231	Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology, 1998, 28, 33-38.	7.3	100
232	PREDICTIVE MODELS OF NATURAL HISTORY IN PRIMARY BILIARY CIRRHOSIS. Clinics in Liver Disease, 1998, 2, 313-331.	2.1	8
233	THE ROLE OF PROGNOSTIC MODELS IN THE TIMING OF LIVER TRANSPLANTATION. Clinics in Liver Disease, 1997, 1, 263-279.	2.1	4
234	Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology, 1997, 26, 22-26.	7.3	100

#	ARTICLE	IF	CITATIONS
235	Cost-Effectiveness of 6 and 12 Months of Interferon- α Therapy for Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 1997, 127, 866.	3.9	138
236	RECURRENCE OF NONALCOHOLIC STEATOHEPATITIS FOLLOWING LIVER TRANSPLANTATION1. <i>Transplantation</i> , 1996, 62, 1802-1805.	1.0	155
237	Models in Clinical Hepatology. , 0, , 2053-2064.		0